Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.


Journal

European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820

Informations de publication

Date de publication:
27 Sep 2024
Historique:
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 27 9 2024
Statut: epublish

Résumé

Cognitive impairment (CI) is one of the most prevalent and burdensome consequences of COVID-19 infection, which can persist up to months or even years after remission of the infection. Current guidelines on post-COVID CI are based on available knowledge on treatments used for improving CI in other conditions. The current review aims to provide an updated overview of the existing evidence on the efficacy of treatments for post-COVID CI. A systematic literature search was conducted for studies published up to December 2023 using three databases (PubMed-Scopus-ProQuest). Controlled and noncontrolled trials, cohort studies, case series, and reports testing interventions on subjects with CI following COVID-19 infection were included. After screening 7790 articles, 29 studies were included. Multidisciplinary approaches, particularly those combining cognitive remediation interventions, physical exercise, and dietary and sleep support, may improve CI and address the different needs of individuals with post-COVID-19 condition. Cognitive remediation interventions can provide a safe, cost-effective option and may be tailored to deficits in specific cognitive domains. Noninvasive brain stimulation techniques and hyperbaric oxygen therapy showed mixed and preliminary results. Evidence for other interventions, including pharmacological ones, remains sparse. Challenges in interpreting existing evidence include heterogeneity in study designs, assessment tools, and recruitment criteria; lack of long-term follow-up; and under-characterization of samples in relation to confounding factors. Further research, grounded on shared definitions of the post-COVID condition and on the accurate assessment of COVID-related CI, in well-defined study samples and with longer follow-ups, is crucial to address this significant unmet need.

Sections du résumé

BACKGROUND BACKGROUND
Cognitive impairment (CI) is one of the most prevalent and burdensome consequences of COVID-19 infection, which can persist up to months or even years after remission of the infection. Current guidelines on post-COVID CI are based on available knowledge on treatments used for improving CI in other conditions. The current review aims to provide an updated overview of the existing evidence on the efficacy of treatments for post-COVID CI.
METHODS METHODS
A systematic literature search was conducted for studies published up to December 2023 using three databases (PubMed-Scopus-ProQuest). Controlled and noncontrolled trials, cohort studies, case series, and reports testing interventions on subjects with CI following COVID-19 infection were included.
RESULTS RESULTS
After screening 7790 articles, 29 studies were included. Multidisciplinary approaches, particularly those combining cognitive remediation interventions, physical exercise, and dietary and sleep support, may improve CI and address the different needs of individuals with post-COVID-19 condition. Cognitive remediation interventions can provide a safe, cost-effective option and may be tailored to deficits in specific cognitive domains. Noninvasive brain stimulation techniques and hyperbaric oxygen therapy showed mixed and preliminary results. Evidence for other interventions, including pharmacological ones, remains sparse. Challenges in interpreting existing evidence include heterogeneity in study designs, assessment tools, and recruitment criteria; lack of long-term follow-up; and under-characterization of samples in relation to confounding factors.
CONCLUSIONS CONCLUSIONS
Further research, grounded on shared definitions of the post-COVID condition and on the accurate assessment of COVID-related CI, in well-defined study samples and with longer follow-ups, is crucial to address this significant unmet need.

Identifiants

pubmed: 39328154
doi: 10.1192/j.eurpsy.2024.1770
pii: S092493382401770X
doi:

Types de publication

Journal Article Systematic Review Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e60

Auteurs

Antonio Melillo (A)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Andrea Perrottelli (A)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Edoardo Caporusso (E)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Andrea Coltorti (A)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.

Giulia Maria Giordano (GM)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Luigi Giuliani (L)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Pasquale Pezzella (P)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Paola Bucci (P)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Armida Mucci (A)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Silvana Galderisi (S)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Mario Maj (M)

World Health Organization (WHO) Collaborating Center, University of Campania "Luigi Vanvitelli", Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH